Victoria Marando
vicmarando.bsky.social
Victoria Marando
@vicmarando.bsky.social
Chemical biologist
Post Doc - Walker Group @ HarvardMicro
PhD - Kiessling Group @ ChemistryMIT
🇨🇦 (go leafs go)
(she/her)
Reposted by Victoria Marando
Excited to share that my first first author paper is now out in @pnas.org ! We show that we can use oxaziridines to label thioether containing glycans in Mtb. Using this approach we could visualize key glycans during model infection! www.pnas.org/doi/10.1073/...
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
www.pnas.org
May 6, 2025 at 10:09 PM
Reposted by Victoria Marando
Lead author @ssmelyansky.bsky.social spearheaded a strategy to label a single sulfur-containing glycan called ManLAM on the cell envelope of the bacteria that cause #TB. news.mit.edu/2025/new-mol... or here: www.pnas.org/doi/10.1073/... 🧪 #glycotime @mitchemistry.bsky.social
New molecular label could lead to simpler, faster tuberculosis tests
MIT chemists found a way to identify a complex sugar molecule in the cell walls of Mycobacterium tuberculosis, the world’s deadliest pathogen. This labeling could lead to simpler, faster TB tests.
news.mit.edu
May 5, 2025 at 9:53 PM
Reposted by Victoria Marando
First post here! To inaugurate this account, I'd like to share my recent work, now published in JACS.

Intercepting a Mycobacterial Biosynthetic Pathway with Covalent Labeling | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/...
Intercepting a Mycobacterial Biosynthetic Pathway with Covalent Labeling
The mycobacterial cell envelope plays both infectious and protective roles. Understanding its structure is crucial for unlocking the molecular basis underlying these functions. Studying glycans, the p...
pubs.acs.org
March 27, 2025 at 6:16 PM
Reposted by Victoria Marando
Well said @dereklowe.bsky.social. Academia produces two vital products: (1) knowledge, and (2) human capital that knows how to use it. If we can’t train enough young creative US scientists to fulfill biopharma industry needs…

“I think they're being short-sighted, because fear does that to you.”
Biopharma companies and CEOs are keeping their heads down at their own peril. They should speak up about what’s happening to the NIH and other science agencies before it’s too late.

Silence gives consent. And no one should consent to this.
Stand Up And Be Counted
www.science.org
February 12, 2025 at 7:41 PM
Reposted by Victoria Marando
Breaking news: The Trump administration cut billions in biomedical funding. Researchers say it imperils work on cancer and other illnesses.
NIH cuts billions of dollars in biomedical funding, effective immediately
The move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease.
www.washingtonpost.com
February 8, 2025 at 5:01 PM